KITE-718 is under clinical development by Gilead Sciences and currently in Phase I for Head And Neck Cancer. According to GlobalData, Phase I drugs for Head And Neck Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KITE-718’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KITE-718 overview

KITE-718 is under development for the treatment of relapsed or refractory solid tumors including urothelial cancer, non-small cell lung cancer, bladder cancer, and head and neck cancer, mantle cell lymphoma, recurrent chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia , diffuse large b-cell lymphoma, acute lymphocytic leukemia, burkitt lymphoma, primary mediastinal b-cell lymphoma, refractory acute myeloid leukemia. The therapeutic candidate is administered as an infusion and constitutes autologous T cells genetically engineered to express T-cell receptors (TCR) targeting cancer cells expressing melanoma associated antigen 3 and 6 and is developed based on engineered autologous cell therapy (eACT) platform.

It was under development for relapsed and refractory multiple myeloma.

Gilead Sciences overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer, and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

For a complete picture of KITE-718’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.